Lakefront Biotherapeutics NV annual depreciation and amortization
2016
2017
2018
2019
2020
2022
2023
2024
2025
Lakefront Biotherapeutics NV Depreciation & Amortization Growth & History (LKFT)
Lakefront Biotherapeutics NV's depreciation and amortization was €55.9M for fiscal 2025.
View full Lakefront Biotherapeutics NV company overviewLakefront Biotherapeutics NV annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €55.9M | €10.4M | +22.80% |
| 2024 | 2024-12-31 | €45.5M | €1.9M | +4.26% |
| 2023 | 2023-12-31 | €43.6M | −€21.9M | −33.44% |
| 2022 | 2022-12-31 | €65.6M | — | — |
| 2020 | 2020-12-31 | €18.7M | €6.2M | +50.08% |
| 2019 | 2019-12-31 | €12.4M | €7.4M | +144.99% |
| 2018 | 2018-12-31 | €5.1M | €796,000 | +18.58% |
| 2017 | 2017-12-31 | €4.3M | €103,000 | +2.46% |
| 2016 | 2016-12-31 | €4.2M | — | — |
Lakefront Biotherapeutics NV depreciation and amortization trends
Over the last five fiscal years, Lakefront Biotherapeutics NV's depreciation and amortization increased from €18.7M to €55.9M, a change of €37.2M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lakefront Biotherapeutics NV source filings ↗